Skip to main content

Table 1 Clinical and demographic data of the BRVO patients

From: Changes of retinal flow volume after intravitreal injection of bevacizumab in branch retinal vein occlusion with macular edema: a case series

No. (Male/Female)

35 (18/17)

Age (yrs)

67.6 ± 11.0

Hypertension

23 (66 %)

  Systolic Blood pressure (mmHg)

131 ± 17

  Diastolic Blood pressure (mmHg)

78 ± 16

OPP (mmHg)

  Baseline

51.1 ± 8.5

  1 month after IVB

51.2 ± 7.6

Hyperlipidemia

15 (43 %)

Duration of BRVO (days)

53.3 ± 40.4

Severity of retinal ischemia (disc area)

26.1 ± 30.1

BCVA (log MAR)

  Baseline

0.62 ± 0.34

  1 month after IVB

0.29 ± 0.27

CMT (μm)

  Baseline

634 ± 235

  1 month after IVB

286 ± 117

  1. BRVO branch retinal vein occlusion, No. number of eyes, OPP ocular perfusion pressure, BCVA best-corrected visual acuity, log MAR logarithm of minimal angle of resolution, IVB intravitreal injection of bevacizumab, CMT central macular thickness